 WESTLAKE VILLAGE, Calif., June 23, 2021 GLOBE NEWSWIRE -- Arcutis Biotherapeutics, Inc. Nasdaq: ARQT, a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that Greg Sukay has joined the company as Vice President, Manufacturing and Process Technologies. Mr. Sukay, who brings more than 25 years of experience in biopharmaceutical operations, will oversee Arcutis external manufacturing and process development for its pipeline of medical dermatology programs. 